When medically indicated, tirzepatide injections in Orlando may help support weight loss by:

• Reducing appetite and food cravings.

• Promoting a feeling of fullness after meals.

• Supporting metabolic regulation.

• Encouraging gradual, sustained weight loss when combined with lifestyle changes.

Individual responses vary.

Tirzepatide may cause side effects in some individuals. A medical consultation is required to review potential risks, benefits, and contraindications.

• As part of our physician-supervised weight loss program in Orlando, tirzepatide is intended to be used alongside a reduced-calorie diet and increased physical activity, not as a stand-alone solution.​

• The most common side effects are usually mild‑to‑moderate gastrointestinal symptoms such as nausea, vomiting, or diarrhea, which tend to occur during dose increases and often lessen over time.

Our Orlando medical weight loss clinic offers a structured, medically supervised program designed for steady, sustainable progress. You may receive weekly subcutaneous injections with ongoing follow-ups, and your dose may be gradually adjusted based on your tolerance, keeping the focus on long-term weight management rather than rapid, short-term loss.

For patients exploring weight loss injections in Orlando, tirzepatide generally produces greater average weight loss than semaglutide at their obesity doses, but both are highly effective options and share similar gastrointestinal side effects and safety considerations. The choice between them often depends on how much weight loss is needed, individual tolerance, access, and cost. Current clinical trial data cited on the page supports that comparison.

Head‑to‑head trial data

• Across multiple datasets, adults with obesity tend to lose a higher percentage of body weight on tirzepatide than on semaglutide when each is used at its typical obesity dose range.​

• In a peer-reviewed publication in the New England Journal of Medicine, results from the SURMOUNT-5 head-to-head trial in adults with obesity/overweight without diabetes showed a mean percent change in body weight at week 72 of −20.2% with tirzepatide versus −13.7% with semaglutide.

• A press summary of the SURMOUNT-5 trial reported that 31.6% of participants on tirzepatide achieved ≥25% weight loss, compared with 16.1% of those on semaglutide (approximately one-third vs one-sixth). Eli Lilly and Company. Lilly’s Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial (press release). December 4, 2024.

Our medical weight loss program in Orlando, FL may be appropriate for adults who:

• Have difficulty losing weight despite lifestyle efforts.

• Are seeking a structured, medically supervised program.

• Want a long-term approach rather than short-term dieting.

• May benefit from additional metabolic support under medical care.

Eligibility is determined through medical consultation.

You may be a good candidate for a medically supervised weight loss program in Orlando if you:

• Have struggled to lose weight despite consistent diet and lifestyle efforts

• Are looking for a structured, physician-guided approach rather than a commercial diet plan

• Want a safe, evidence-based option focused on long-term weight management

• Are willing to participate in ongoing medical monitoring and follow-up

• Understand that weight loss results vary and require commitment to the program

Medical weight loss is not a one-size-fits-all solution. Eligibility is determined through a medical evaluation, which includes a review of your health history, current medications, and overall goals.